volume 295, issue 6592, P228-229 1987
DOI: 10.1136/bmj.295.6592.228
View full text
|
|
Share

Abstract: trial comparing the efficacy of subcutaneous low dose cytarabine alone or in combination with isotretinoin versus supportive treatment alone. The therapeutic potential of interferons, haemopoietic growth factors, and other biological response modifiers is currently being evaluated. Preliminary results suggest that these may provide a novel strategy for treating myelodysplastic syndromes.